Table 1.
FDA-Cleared Multiplex Assays for Detection of Influenza and Other Respiratory Viruses (October 2020)
| Manufacturer (use) | Product | Platform/instrument | Viruses detected |
Complexity | |
|---|---|---|---|---|---|
| Influenza | Other respiratory viruses | ||||
| BioFire Diagnostics (commercially available) | BioFire Respiratory Panel 2.1 (RP2.1) | FilmArray 2.0 and FilmArray Torch systems | A and B | SARS-CoV-2 Parainfluenza virus 1-4 |
High Moderate |
| QIAGEN (commercially available) | QIAstat-Dx Respiratory SARS-CoV-2 Panel | QIAstat Dx Analyzer 1.0 system | A and B | SARS-CoV-2 Parainfluenza virus 1-4 |
High Moderate |
| CDC (public health use only, not commercially available) | Influenza SARS-CoV-2 (Flu SC2) Multiplex Assay | Applied Biosystems 7500 Fast Dx Real-Time PCR Instrument | A and B | SARS-CoV-2 | High |
| Roche Diagnostics41 | cobas SARS-CoV-2 & Influenza A/B | cobas 6800/8800 Systems real-time PCR instrument | A and B | SARS-CoV-2 | High |
| Roche Diagnostics42 | cobas SARS-CoV-2 & Influenza A/B | cobas Liat System real-time PCR instrument | A and B | SARS-CoV-2 | High |
CDC, Centers for Disease Control and Prevention; FDA, United States Food and Drug Administration; PCR, polymerase chain reaction; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2.